

## BioSmart Research Announces Break Through Cannabinoid Isolate Formulas with Potential Health Benefits

BioSmart Manufactures Highly Concentrated THC-FREE Isolate & Terpene Formulas for Treating Specific Health Conditions

YELM, WASHINGTON, U.S.A., July 20, 2021 /EINPresswire.com/ -- After 3 years of research, BioSmart rolled out its professional product line of THC-Free cannabinoid and terpenoid formulas for professional distribution to health care professionals.

BioSmart's formulas combine specific terpenes with selected cannabinoids that work synergistically with each other to gain the health benefits derived from its products. BioSmart"s specialty formulas target <u>pain management with CBD</u>.



Clinical dosing with CBD

BioSmart uses proprietary high-pressure liquid chromatography to isolate and concentrate its formulas. Biosmart's formulas are concentrated to achieve the clinical dosing requirements indicated in clinical studies Because the formulas are derived from Hemp, and totally free of

psychoactive ingredients, BioSmart is able to market its formulas domestically without a prescription to qualified adults through healthcare providers and selected retail outlets.

"We have barely begun to understand the therapeutic potential of cannabis," says Ethan Russo, a neurologist and director of R&D at the International Cannabis and Cannabinoids Institute, based in the Czech Republic. "We haven't taken the steps that are required to really harness the abilities of some of these minor cannabinoids, particularly in conjunction with optimized terpenoid profiles."

In order to advance its research, initiate clinical trials, and expand the sharing of its research with

health care professionals, Biosmart has opened a Schedule CF offering through the WeFunder platform in order to raise the capital necessary to achieve its ongoing objectives.

For investment information: <u>https://wefunder.com/biosmart.resear</u> <u>ch.inc</u>

For distribution opportunities: <u>https://biosmartresearchcbd.com/prof</u> <u>essional-sign-up/</u>

Or contact: Renee Searle, CEO – renee@biosmartresearch.com 360.888.2893 www.biosmartresearchcbd.com

Renee Searle BioSmart Research Inc +1 360-888-2893 email us here Visit us on social media: Facebook Twitter LinkedIn



This press release can be viewed online at: https://www.einpresswire.com/article/546394694

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.